- Home
- ZIM vs LQDA Comparison
ZIM vs LQDA Comparison
Compare ZIM & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIM
- LQDA
- Stock Information
- Founded
- ZIM 1945
- LQDA 2004
- Country
- ZIM Israel
- LQDA United States
- Employees
- ZIM N/A
- LQDA N/A
- Industry
- ZIM Marine Transportation
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- ZIM Consumer Discretionary
- LQDA Health Care
- Exchange
- ZIM Nasdaq
- LQDA Nasdaq
- Market Cap
- ZIM 1.6B
- LQDA 1.9B
- IPO Year
- ZIM 2021
- LQDA 2018
- Fundamental
- Price
- ZIM $13.50
- LQDA $24.22
- Analyst Decision
- ZIM Sell
- LQDA Strong Buy
- Analyst Count
- ZIM 4
- LQDA 9
- Target Price
- ZIM $13.27
- LQDA $32.67
- AVG Volume (30 Days)
- ZIM 4.5M
- LQDA 2.9M
- Earning Date
- ZIM 11-19-2025
- LQDA 11-12-2025
- Dividend Yield
- ZIM 52.89%
- LQDA N/A
- EPS Growth
- ZIM N/A
- LQDA N/A
- EPS
- ZIM 16.63
- LQDA N/A
- Revenue
- ZIM $8,575,100,000.00
- LQDA $19,322,000.00
- Revenue This Year
- ZIM N/A
- LQDA $405.58
- Revenue Next Year
- ZIM N/A
- LQDA $373.93
- P/E Ratio
- ZIM $0.81
- LQDA N/A
- Revenue Growth
- ZIM 43.57
- LQDA 30.20
- 52 Week Low
- ZIM $11.04
- LQDA $9.71
- 52 Week High
- ZIM $30.15
- LQDA $29.94
- Technical
- Relative Strength Index (RSI)
- ZIM 39.30
- LQDA 51.93
- Support Level
- ZIM $13.48
- LQDA $21.35
- Resistance Level
- ZIM $14.10
- LQDA $23.33
- Average True Range (ATR)
- ZIM 0.39
- LQDA 1.19
- MACD
- ZIM -0.00
- LQDA -0.07
- Stochastic Oscillator
- ZIM 4.19
- LQDA 69.54
About ZIM ZIM Integrated Shipping Services Ltd.
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.